Psoriasis | Unmet Need | Moderate to Severe Psoriasis | US/EU | 2025
With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space for drug developers. In recent years, this market has slowly shifted from the use of established TNF-alpha inhibitors as early-line agents to the early-line use of non-TNF biologics such as IL-17 inhibitors (e.g., Cosentyx, Taltz) and IL-23 inhibitors (e.g., Tremfya, Skyrizi), and oral targeted therapies such as PDE4 inhibitors (Otezla). The market has also witnessed the launch of the oral TYK2 inhibitor Sotyktu and the fourth-in-class IL-17 inhibitor Bimzelx. Despite the availability of multiple treatments for psoriasis, substantial unmet need remains. Novel agents are needed that can differentiate themselves on the attributes of efficacy, safety, delivery, and ability to treat a broad patient population.
QUESTIONS ANSWERED
- How do dermatologists rate the performances of Bimzelx, Sotyktu, and their competitors on key treatment drivers and goals for moderate to severe psoriasis?
- Are drug attributes such as skin clearance, sustained efficacy, and ease of administration key influencers, have they limited impact, or are they hidden opportunities?
- What are the greatest unmet needs and most attractive opportunities in the treatment of moderate to severe psoriasis?
- What trade-offs across key clinical / nonclinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new drug for moderate to severe psoriasis?
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers
- Analyze market scenarios for different target product profiles using the TPP Simulator
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 34 European dermatologists fielded in January 2025
Key companies: AbbVie, Eli Lilly, UCB, Johnson & Johnson Innovative Medicine, Amgen, Bristol Myers Squibb
Key drugs: Humira, Taltz, Bimzelx, Stelara, Skyrizi, Otezla, Sotyktu
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
